Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma...

Area of Science:

• Biomedical Engineering
• Respiratory Medicine
• Nanotechnology

Background:

• Asthma management is challenging due to therapies lacking targeted molecular pathways.
• Current treatments offer broad immunosuppression and bronchodilation, not disease-specific solutions.
• Efficient delivery of genetic therapies like small interfering RNA (siRNA) to airway epithelial cells (AECs) is a major hurdle for asthma treatment.

Purpose of the Study:

• To develop an efficient, inhalable siRNA delivery system targeting AECs for asthma therapy.
• To create novel nanovesicles from mesenchymal stem cells for targeted siRNA delivery.
• To investigate and optimize parameters for effective nebulized nanovesicle-based siRNA delivery.

Main Methods:

• Artificially prepared nanovesicles were created using designed extrusion processes of mesenchymal stem cells.
• Orthogonal testing was used to optimize parameters like extrusion cycles, pore sizes, and centrifugal forces for inhalation delivery.
• The nanovesicles were tested for their ability to deliver thymic stromal lymphopoietin-targeted siRNA into AECs in ovalbumin-induced asthma models.

Main Results:

• Optimized nanovesicles demonstrated efficient delivery of siRNA into AECs.
• The treatment significantly suppressed asthma-related inflammatory pathways and goblet cell hyperplasia.
• Significant inhibition of asthma symptoms was observed in animal models.

Conclusions:

• A novel nebulized nanovesicle-based carrier enables effective local inhalation delivery of siRNA.
• This platform shows promise for treating asthma and potentially other respiratory diseases.
• The study provides a new therapeutic delivery strategy for targeted genetic intervention in respiratory conditions.